Radium-223 ChlorideA New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma

被引：5
|
作者：
Álvaro Pinto
Patricia Cruz
机构：
[1] University Hospital La Paz - IdiPAZ,Medical Oncology Department
来源：
Drugs in R&D | 2012年 / 12卷 / 4期
关键词：
Overall Survival; Docetaxel; Zoledronic Acid; Denosumab; Abiraterone;
D O I：
10.2165/11636250-000000000-00000
中图分类号：
学科分类号：
摘要：
In the last few years, the treatment of castration-resistant prostate carcinoma (CRPC) has changed completely. The approval of docetaxel and subsequent investigation in this field have led to development of new agents that have demonstrated an improvement in overall survival in the post-docetaxel setting, such as cabazitaxel and abiraterone. Radium-223 chloride is a radioisotope that has recently shown efficacy after docetaxel and in patients unfit for docetaxel, with improvements in overall survival and the time to the first skeletal-related event, compared with placebo, without increasing toxicity. These findings have made this agent a new option for treatment of these patients in the near future.
引用
收藏
页码：227 / 233
页数：6
相关论文
共 50 条
  • [21] Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
    Peters, Michel L.
    de Meijer, Claudine
    Wyndaele, Dirk
    Noordzij, Walter
    Leliveld-Kors, Annemarie M.
    van den Bosch, Joan
    van den Berg, Pieter H.
    Baka, Agni
    Gaultney, Jennifer G.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (01) : 133 - 143
  • [22] Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging
    Iizuka, Junpei
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 16 - 23
  • [23] Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223
    Mukherji, Deborah
    El Dika, Imane
    Temraz, Sally
    Haidar, Mohammed
    Shamseddine, Ali
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 373 - 380
  • [24] Radium-223 Dichloride in Peritoneal Dialysate Following Treatment of Metastatic Castration-resistant Prostate Cancer
    Saganich, Christopher
    Zgaljardic, Michael
    HEALTH PHYSICS, 2022, 122 (03): : 433 - 439
  • [25] Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223
    Odo, Ugochukwu
    Vasudevamurthy, Ashwin K.
    Sartor, Oliver
    CLINICAL GENITOURINARY CANCER, 2017, 15 (03) : E501 - E502
  • [26] Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer
    Wong, William W.
    Anderson, Eric M.
    Mohammadi, Homan
    Daniels, Thomas B.
    Schild, Steve E.
    Keole, Sameer R.
    Choo, C. Richard
    Tzou, Katherine S.
    Bryce, Alan H.
    Ho, Thai H.
    Quevedo, Fernando J.
    Vora, Sujay A.
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : E969 - E975
  • [27] Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients
    Marie Øbro Fosbøl
    Peter Meidahl Petersen
    Gedske Daugaard
    Søren Holm
    Andreas Kjaer
    Jann Mortensen
    Annals of Nuclear Medicine, 2018, 32 : 16 - 21
  • [28] Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients
    Fosbol, Marie Obro
    Petersen, Peter Meidahl
    Daugaard, Gedske
    Holm, Soren
    Kjaer, Andreas
    Mortensen, Jann
    ANNALS OF NUCLEAR MEDICINE, 2018, 32 (01) : 16 - 21
  • [29] The Timing of Radium-223 Therapy in Castration-Resistant Prostate Cancer
    Sartor, Oliver
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 570 - 572
  • [30] Prognostic biomarkers in the use of radium-223 in patients with metastatic castration-resistant prostate cancer
    Vidal, M.
    Cardenas-Perilla, R.
    Delgado, A.
    Moron, S.
    Blair, J. L. Londono
    Vega, I.
    Ochoa, J. J. Correa
    Rojas, J.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (05): : 310 - 317
12345